An observational study in Extracorporeal Membrane Oxygenation and Acute Respiratory Distress Syndrome, sponsored by Charite University, Berlin, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Charite University, Berlin, Germany · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Respiratory Distress Syndrome with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Respiratory Distress Syndrome · Germany.
Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, this one is the 14th largest by enrollment of the 21 observational ones that give a count, is one of 13 that started in 2020, is one of 22 observational ones, and was the 36th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →7 of the 48 studies in Respiratory Distress Syndrome with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Tuebingen · Sites in Germany
Ages 18+
BioAegis Therapeutics Inc. · Sites in Germany, United States, Belgium and 10 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Germany, Switzerland
Ages 23 wk–31 wk
University Hospital Tuebingen · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 7
First in 2003; this study’s year is marked. 13 started in 2020.
This study's enrollment of 77 is below the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 114 across the 26 interventional studies, 132 across the 21 observational. Of the 28 that completed or were terminated, 4 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 48 have an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Charite University, Berlin, Germany has 4 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Respiratory Distress Syndrome with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05947955BioAegis Therapeutics Inc.Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO blood flow is possible using Rf measurements.
A prospective, observational study will be performed measuring the Rf of total ECMO blood flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an ultrasound dilution technique.
ECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured Rf as long as systemic oxygenation is not compromised.
Based on data from the 'Blood Recirculation and vvECMO' trial (ClinicalTrials.gov ID: NCT03200314) (i.e. an expected frequency of successful blood flow reduction of 66.7%), using a one-sample Chi square test, a two-sided type-1 error of 5%, a power of 80%, a total of 68 patients is needed to show that the proportion of patients with a secure ECMO blood flow reduction is greater than 50%. Presumably, 136 Patients have to be included into the trial to study 68 patients with a relevant Rf since not all patients on V-V ECMO suffer from a high Rf.
Inclusion Criteria:
Exclusion Criteria:
Patients aged 18 years or older requiring veno-venous ECMO for treatment of hypoxemia in ARDS.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Successful ECMO blood flow reduction
Number of patients with a relevant recirculation fraction and successful ECMO blood flow reduction
Time frame: Once within the first week after initiation of ECMO therapy
Recirculation fraction
Fraction of blood recirculating through the ECMO circuit
Time frame: Once within the first week after initiation of ECMO therapy
Arterial blood oxygen content
Arterial blood oxygen content before vs. after reduction of ECMO blood flow
Time frame: Once within the first week after initiation of ECMO therapy
Extracorporeal blood Flow
ECMO Blood Flow before vs. after reduction of ECMO blood flow
Time frame: Once within the first week after initiation of ECMO therapy
Extracorporeal gas flow
ECMO Sweep Gas flow
Time frame: Once within the first week after initiation of ECMO therapy
Length of ECMO therapy
Days on ECMO
Time frame: Daily until the end of ECMO therapy (approximately 14 days)
Cannula position and distance
The distance between the tip of drainage and return cannula will be measured in the existing medical imaging (e.g. CT scans)
Time frame: Once within the first week after initiation of ECMO therapy
Right heart dysfunction
Existing echocardiography will be evaluated for possible right heart dysfunction
Time frame: Once within the first week after initiation of ECMO therapy
Length of mechanical ventilation
Length of mechanical ventilation
Time frame: Entire duration of the ICU stay (approximately 28 days)
Complications of ECMO therapy
Incidence of cannula or system changes (i.e. due to circuit clotting), complications attributed to ECMO therapy like bleeding complications from the cannulation site, transfusion requirements, hemolysis
Time frame: Length of ECMO therapy (approximately 14 days)
ICU mortality
ICU mortality
Time frame: Entire duration of the ICU stay (approximately 28 days)
ICU length of stay
ICU length of stay
Time frame: Entire duration of the ICU stay (approximately 28 days)
Incidence of ICU-acquired organ dysfunctions and complications
Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions, ICU-acquired infections
Time frame: Entire duration of the ICU stay (approximately 28 days)
ECMO blood flow over time
ECMO blood and sweep gas flow over time
Time frame: Daily until the end of ECMO therapy (approximately 14 days)
ECMO sweep gas flow over time
ECMO sweep gas flow over time
Time frame: Daily until the end of ECMO therapy (approximately 14 days)
Mobility at ICU discharge
Level of mobility the patient has reached at ICU discharge (recumbent, sitting, standing, walking with help, walking independently)
Time frame: Discharge from the ICU (approximately 28 days)
Weaning level at ICU discharge
Level of weaning reached at ICU discharge
Time frame: Discharge from the ICU (approximately 28 days)
Status of mechanical ventilation at ICU discharge
Status of mechanical ventilation at ICU discharge including all relevant settings and parameters
Time frame: Discharge from the ICU (approximately 28 days)
Level of organ dysfunction at ICU discharge
Sepsis-related Organ Failure Assessment Score at ICU discharge
Time frame: Discharge from the ICU (approximately 28 days)
Level of consciousness at ICU discharge
Glasgow Coma Scale at ICU discharge
Time frame: Discharge from the ICU (approximately 28 days)
Level of disease severity
Acute Physiology And Chronic Health Evaluation at ICU discharge
Time frame: Discharge from the ICU (approximately 28 days)
Hospital acquired infections related to ECMO therapy
Infection/colonisation of the ECMO circuit
Time frame: Entire duration of ECMO therapy
Bleeding and thrombembolic complications of ECMO therapy
Bleeding complications, thrombembolic events, overall use of blood products and coagulation factors, electron microscopic evaluation of selected membranes after change or weaning of the ECMO circuit
Time frame: Entire duration of ECMO therapy
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2020 to primary completion in May 2026, 65 months.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 65 months is above that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → May 2026 and completion Oct 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Charite University, Berlin, Germany →